Current progress of DNA vaccine studies in humans

• Tang DC, Devit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature356(6365), 152–154 (1992).
   PubMed Web of Science ®Google Scholar
• Ulmer JB, Donnelly JJ, Parker SE et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science259(5102), 1745–1749 (1993).
   PubMed Web of Science ®Google Scholar
• Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, Robinson HL. DNA vaccines: protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl Acad. Sci. USA90(24), 11478–11482 (1993).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Hunt LA, Webster RG. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine11(9), 957–960 (1993).
   PubMed Web of Science ®Google Scholar
• Yankauckas MA, Morrow JE, Parker SE et al. Long-term anti-nucleoprotein cellular and humoral immunity is induced by intramuscular injection of plasmid DNA containing NP gene. DNA Cell Biol.12(9), 771–776 (1993).
   PubMed Web of Science ®Google Scholar
• Wang B, Ugen KE, Srikantan V et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc. Natl Acad. Sci. USA90(9), 4156–4160 (1993).
   PubMed Web of Science ®Google Scholar
• Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology209(1), 147–154 (1995).
   PubMed Web of Science ®Google Scholar
• Davis HL, Michel ML, Whalen RG. DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody. Hum. Mol. Genet.2(11), 1847–1851 (1993).
   PubMed Web of Science ®Google Scholar
• Cox GJ, Zamb TJ, Babiuk LA. Bovine herpesvirus 1: immune responses in mice and cattle injected with plasmid DNA. J. Virol.67(9), 5664–5667 (1993).
   PubMed Web of Science ®Google Scholar
• Lu S, Arthos J, Montefiori DC, Yasutomi Y et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol.70(6), 3978–3991 (1996).
   PubMed Web of Science ®Google Scholar
• Boyer JD, Ugen KE, Wang B et al. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination. Nat. Med.3(5), 526–532 (1997).
   PubMed Web of Science ®Google Scholar
• Lodmell DL, Ray NB, Parnell MJ et al. DNA immunization protects nonhuman primates against rabies virus. Nat. Med.4(8), 949–952 (1998).
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J. Infect. Dis.178(1), 92–100 (1998).
   PubMed Web of Science ®Google Scholar
• Wang R, Doolan DL, Le TP et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science282(5388), 476–480 (1998).
   PubMed Web of Science ®Google Scholar
• Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine24(21), 4475–4481 (2006).
   PubMed Web of Science ®Google Scholar
• Egan MA, Megati S, Roopchand V et al. Rational design of a plasmid DNA vaccine capable of eliciting cell-mediated immune responses to multiple HIV antigens in mice. Vaccine24(21), 4510–4523 (2006).
   PubMed Web of Science ®Google Scholar
• Peachman KK, Rao M, Alving CR. Immunization with DNA through the skin. Methods31(3), 232–242 (2003).
   PubMed Web of Science ®Google Scholar
• Trimble C, Lin CT, Hung CF et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine21(25–26), 4036–4042 (2003).
   Google Scholar
• Herrmann JE, Chen SC, Jones DH et al. Immune responses and protection obtained by oral immunization with rotavirus VP4 and VP7 DNA vaccines encapsulated in microparticles. Virology259(1), 148–153 (1999).
   PubMed Web of Science ®Google Scholar
• Chen SC, Jones DH, Fynan EF et al. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol.72(7), 5757–5761 (1998).
   PubMed Web of Science ®Google Scholar
• Selinsky C, Luke C, Wloch M et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum. Vaccin.1(1), 16–23 (2000).
   Google Scholar
• Vilalta A, Mahajan RK, Hartikka J et al. I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration. Hum. Gene Ther.16(10), 1143–1150 (2005).
   PubMed Web of Science ®Google Scholar
• Wloch MK, Boutsaboualoy S, Han C, Smith LR. Detection of antigen specific memory T-cell responses after vaccination with a cytomegalovirus DNA vaccine. Presented at: 11th International CMV 2007 Workshop. Toulouse, France, 13–17 May 2007.
   Google Scholar
• Livingston JB, Lu S, Robinson H, Anderson DJ. Immunization of the female genital tract with a DNA-based vaccine. Infect. Immun.66(1), 322–329 (1998).
   PubMed Web of Science ®Google Scholar
• Fuller D, Loudon P, Schmaljohn C. Preclinical and clinical progress of particle-mediated DNA vaccines for infectious diseases. Methods40(1), 86–97 (2006).
   PubMed Web of Science ®Google Scholar
• Sharpe M, Lynch D, Topham S, Major D, Wood J, Loudon P. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine25(34), 6392–6398 (2007).
   PubMed Web of Science ®Google Scholar
• Tsang C, Babiuk S, van Drunen Littel-van den Hurk S, Babiuk LA, Griebel P. A single DNA immunization in combination with electroporation prolongs the primary immune response and maintains immune memory for six months. Vaccine25(30), 5485–5494 (2007).
   PubMed Web of Science ®Google Scholar
• Widera G, Austin M, Rabussay D et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol.164(9), 4635–4640 (2000).
   PubMed Web of Science ®Google Scholar
• Dupuis M, Denis-Mize K, Woo C et al. Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice. J. Immunol.165(5), 2850–2858 (2000).
   PubMed Web of Science ®Google Scholar
• Luckay A, Sidhu MK, Kjeken R et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol.81(10), 5257–5269 (2007).
   PubMed Web of Science ®Google Scholar
• Hooper J, Golden J, Ferro A, King A. Smallpox DNA vaccine delivered by novel skin electroporation device protects mice against intranasal poxvirus challenge. Vaccine25(10), 1814–1823 (2007).
   PubMed Web of Science ®Google Scholar
• Babiuk LA, Pontarollo R, Babiuk S, Loehr B, van Drunen Littel-van den Hurk S. Induction of immune responses by DNA vaccines in large animals. Vaccine21(7–8), 649–658 (2003).
   PubMed Web of Science ®Google Scholar
• Tollefsen S, Vordermeier M, Olsen I et al. DNA injection in combination with electroporation: a novel method for vaccination of farmed ruminants. Scand. J. Immun.57(3), 229–238 (2003).
   PubMed Web of Science ®Google Scholar
• Wang Z, Troilo PJ, Wang X et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther.11(8), 711–721 (2004).
   PubMed Web of Science ®Google Scholar
• Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Exp. Opin. Drug Deliv.2(2), 255–268 (2005).
   PubMedGoogle Scholar
• Robinson HL. Prime boost vaccines power up in people. Nat. Med.9(6), 642–643 (2003).
   PubMed Web of Science ®Google Scholar
• Casimiro D, Chen L, Fu T-M et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol.77(11), 6305–6313 (2003).
   PubMed Web of Science ®Google Scholar
• Casimiro D, Tang A, Chen L et al. Vaccine-induced immunity in baboons by using DNA and replication-incompetent adenovirus type 5 vectors expressing a human immunodeficiency virus type 1 gag gene. J. Virol.77(13), 7663–7668 (2003).
   PubMed Web of Science ®Google Scholar
• Wu L, Kong WP, Nabel GJ. Enhanced breadth of CD4 T-cell immunity by DNA prime and adenovirus boost immunization to human immunodeficiency virus Env and Gag immunogens. J. Virol.79(13), 8024–8031 (2005).
   PubMed Web of Science ®Google Scholar
• Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature415(6869), 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• Dunachie SJ, Walther M, Epstein JE et al. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun.74(10), 5933–5942 (2006).
   PubMed Web of Science ®Google Scholar
• Cebere I, Dorrell L, McShane H et al. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine24(4), 417–425 (2006).
   PubMed Web of Science ®Google Scholar
• McConkey SJ, Reece WH, Moorthy VS et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med.9(6), 729–735 (2003).
   PubMed Web of Science ®Google Scholar
• Hanke T, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol.88(Pt 1), 1–12 (2007).
   PubMed Web of Science ®Google Scholar
• Webster DP, Dunachie S, McConkey S et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine24(15), 3026–3034 (2006).
   PubMed Web of Science ®Google Scholar
• Kelleher AD, Puls RL, Bebbington M et al. A randomized, placebo-controlled Phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS20(2), 294–297 (2006).
   PubMed Web of Science ®Google Scholar
• Egan MA, Chong SY, Megati S et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res. Hum. Retroviruses21(7), 629–643 (2005).
   PubMed Web of Science ®Google Scholar
• Wang R, Epstein J, Charoenvit Y et al. Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein. J. Immunol.172(9), 5561–5569 (2004).
   PubMed Web of Science ®Google Scholar
• Wang S, Kennedy J, West K et al. Balanced cellular and antibody responses induced by the polyvalent DNA prime–protein boost HIV-1 vaccine formulation DP6–001 in healthy human volunteers. Vaccine (2008) (In Press).
   Google Scholar
• Biswas S, Reddy GS, Srinivasan VA, Rangarajan PN. Preexposure efficacy of a novel combination DNA and inactivated rabies virus vaccine. Hum. Gene Ther.12(15), 1917–1922 (2001).
   PubMed Web of Science ®Google Scholar
• Barouch DH, McKay PF, Sumida SM et al. Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming–viral vector boosting human immunodeficiency virus type 1 vaccines. J. Virol.77(16), 8729–8735 (2003).
   PubMed Web of Science ®Google Scholar
• McDonnell WM, Askari FK. DNA vaccines. N. Enlg. J. Med.334(1), 42–45 (1996).
   PubMed Web of Science ®Google Scholar
• Cohen J. AIDS research. Did Merck’s failed HIV vaccine cause harm? Science318(5853), 1048–1049 (2007).
   PubMed Web of Science ®Google Scholar
• Precopio ML, Betts MR, Parrino J et al. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med.204(6), 1405–1416 (2007).
   PubMed Web of Science ®Google Scholar
• Casazza JP, Betts MR, Price DA et al. Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J. Exp. Med.203(13), 2865–2877 (2006).
   PubMed Web of Science ®Google Scholar
• Roy MJ, Wu MS, Barr LJ et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine19(7–8), 764–778 (2000).
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Brazolot Millan CL et al. Route and method of delivery of DNA vaccine influence immune responses in mice and non-human primates. Mol. Med.5(5), 287–300 (1999).
   PubMed Web of Science ®Google Scholar
• Pertmer TM, Roberts TR, Haynes JR. Influenza virus nucleoprotein-specific immunoglobulin G subclass and cytokine responses elicited by DNA vaccination are dependent on the route of vector DNA delivery. J. Virol.70(9), 6119–6125 (1996).
   PubMed Web of Science ®Google Scholar
• Feltquate DM, Heaney S, Webster RG, Robinson HL. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immun.158(5), 2278–2284 (1997).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Roy MJ, Widera G, Swain WF, Broome S, Edelman R. Phase I safety and immune response studies of a DNA vaccine encoding hepatitis B surface antigen delivered by a gene delivery device. Vaccine17(22), 2826–2829 (1999).
   PubMed Web of Science ®Google Scholar
• Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine21(31), 4604–4608 (2003).
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology40(4), 874–882 (2004).
   PubMed Web of Science ®Google Scholar
• Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel ML. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine24(21), 4482–4489 (2006).
   PubMed Web of Science ®Google Scholar
• Clements-Mann ML, Eichelberger M, Boslego JW et al. Safety and immunogenicity of influeza hemagglutinin DNA-vaccine alone or with aluminum adjuvant in adult volunteers. Presented at: 17th Annual Meeting of the American Society for Virology. Vancover, British Columbia, Canada, 11–15 July 1998.
   Google Scholar
• Wang R, Epstein J, Baraceros FM et al. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc. Natl Acad. Sci. USA98(19), 10817–10822 (2001).
   PubMed Web of Science ®Google Scholar
• Le TP, Coonan KM, Hedstrom RC et al. Safety, tolerability and humoral immune responses after intramuscular administration of a malaria DNA vaccine to healthy adult volunteers. Vaccine18(18), 1893–1901 (2000).
   PubMed Web of Science ®Google Scholar
• Gilbert SC, Moorthy VS, Andrews L et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine24(21), 4554–4561 (2006).
   PubMed Web of Science ®Google Scholar
• Moorthy VS, McConkey S, Roberts M et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine21(17–18), 1995–2002 (2003).
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Pinder M, Reece WH et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J. Infect. Dis.188(8), 1239–1244 (2003).
   PubMed Web of Science ®Google Scholar
• Moorthy VS, Imoukhuede EB, Keating S et al. Phase I evaluation of 3 highly immunogenic prime–boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men. J. Infect. Dis.189(12), 2213–2219 (2004).
   PubMed Web of Science ®Google Scholar
• Vuola JM, Keating S, Webster DP et al. Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J. Immunol.174(1), 449–455 (2005).
   PubMed Web of Science ®Google Scholar
• Epstein JE, Charoenvit Y, Kester KE et al. Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A. Vaccine22(13–14), 1592–1603 (2004).
   PubMed Web of Science ®Google Scholar
• Wang R, Richie TL, Baraceros MF et al. Boosting of DNA vaccine-elicited g interferon responses in humans by exposure to malaria parasites. Infect. Immun.73(5), 2863–2872 (2005).
   PubMed Web of Science ®Google Scholar
• Boyer JD, Chattergoon MA, Ugen KE et al. Enhancement of cellular immune response in HIV-1 seropositive individuals: a DNA-based trial. Clinical Immunol.90(1), 100–107 (1999).
   PubMed Web of Science ®Google Scholar
• Danko I, Fritz JD, Jiao S, Hogan K, Latendresse JS, Wolff JA. Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Ther.1(2), 114–121 (1994).
   PubMed Web of Science ®Google Scholar
• Weber R, Bossart W, Cone R, Luethy R, Moelling K. Phase I clinical trial with HIV-1 gp160 plasmid vaccine in HIV-1-infected asymptomatic subjects. Eur. J. Clin. Microbiol. Infect. Dis.20(11), 800–803 (2001).
   PubMed Web of Science ®Google Scholar
• Calarota S, Bratt G, Nordlund S et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet351(9112), 1320–1325 (1998).
   PubMed Web of Science ®Google Scholar
• Hejdeman B, Bostrom AC, Matsuda R et al. DNA immunization with HIV early genes in HIV type 1-infected patients on highly active antiretroviral therapy. AIDS Res. Hum. Retroviruses20(8), 860–870 (2004).
   PubMed Web of Science ®Google Scholar
• Boyer JD, Cohen AD, Vogt S et al. Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of β-chemokines. J. Infect. Dis.181(2), 476–483 (2000).
   PubMed Web of Science ®Google Scholar
• MacGregor R, Ginsberg R, Ugen K et al. T-cell responses induced in normal volunteers immunized with a DNA-based vaccine containing HIV-1 env and rev. AIDS16(16), 2137–2143 (2002).
   PubMed Web of Science ®Google Scholar
• Shiver JW. Current Issues in the clinical evaluation of vaccines. Presented at: HIV Vaccine Development: Progress and Prospects. Whistler, British Columbia, Canada, 12–18 April 2004.
   Google Scholar
• Mulligan MJ, Russell ND, Celum C et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res. Hum. Retroviruses22(7), 678–683 (2006).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science292(5514), 69–74 (2001).
   PubMed Web of Science ®Google Scholar
• Tavel JA, Martin JE, Kelly GG et al. Safety and immunogenicity of a gag-pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir. Immune Defic. Syndr.44(5), 601–605 (2007).
   PubMed Web of Science ®Google Scholar
• Mwau M, Cebere I, Sutton J et al. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol.85(Pt 4), 911–919 (2004).
   PubMed Web of Science ®Google Scholar
• Peters BS, Jaoko W, Vardas E et al. Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine25(11), 2120–2127 (2007).
   PubMed Web of Science ®Google Scholar
• Graham BS, Koup RA, Roederer M et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis.194(12), 1650–1660 (2006).
   PubMed Web of Science ®Google Scholar
• Catanzaro AT, Koup RA, Roederer M et al. Phase I safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis.194(12), 1638–1649 (2006).
   PubMed Web of Science ®Google Scholar
• Barouch DH, Yang ZY, Kong WP et al. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J. Virol.79(14), 8828–8834 (2005).
   PubMed Web of Science ®Google Scholar
• Wang S, Farfan-Arribas DJ, Shen S et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 env DNA vaccine. Vaccine24(21), 4531–4540 (2006).
   PubMed Web of Science ®Google Scholar
• Lu S, Wyatt R, Richmond JF et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses14(2), 151–155 (1998).
   PubMed Web of Science ®Google Scholar
• Chakrabarti BK, Kong WP, Wu BY et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J. Virol.76(11), 5357–5368 (2002).
   PubMed Web of Science ®Google Scholar
• Martin J, Sullivan N, Enama M et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol.13(11), 1267–1277 (2006).
   PubMed Web of Science ®Google Scholar
• Schmaljohn C. DNA vaccines for biodefense. Presented at: DNA Vaccines. Malaga, Spain, 23–25 May 2007.
   Google Scholar
• Wu TC. Therapeutic human papillomavirus DNA vaccination strategies to control cervical cancer. Eur. J. Immun.37(2), 310–314 (2007).
   PubMed Web of Science ®Google Scholar
• zur Hausen H. Papillomavirus infections – a major cause of human cancers. Biochim. Biophys. Acta.1288(2), F55–F78 (1996).
   PubMed Web of Science ®Google Scholar
• Klencke B, Matijevic M, Urban RG et al. Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin. Cancer Res.8(5), 1028–1037 (2002).
   PubMed Web of Science ®Google Scholar
• Sheets EE, Urban RG, Crum CP et al. Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. Am. J. Obstet. Gynecol.188(4), 916–926 (2003).
   PubMed Web of Science ®Google Scholar
• Garcia F, Petry KU, Muderspach L et al. ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial. Obstet. Gynecol.103(2), 317–326 (2004).
   PubMed Web of Science ®Google Scholar
• Hersh EM, Akporiaye E, Harris D et al. Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Hum. Gene Ther.5(11), 1371–1384 (1994).
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Hersh EM, Akporiaye ET et al. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J. Clin. Oncol.15(1), 341–349 (1997).
   PubMed Web of Science ®Google Scholar
• Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin. Cancer Res.5(10), 2766–72 (1999).
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Lestingi TM, Sudakoff G, Kradjian SA. Phase I study of immunotherapy of metastatic renal cell carcinoma by direct gene transfer into metastatic lesions. Hum. Gene Ther.5(11), 1357–1370 (1994).
   PubMed Web of Science ®Google Scholar
• Galanis E, Burch PA, Richardson RL et al. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Cancer101(11), 2557–2566 (2004).
   PubMed Web of Science ®Google Scholar
• Belldegrun A, Tso CL, Zisman A et al. Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology. Hum. Gene Ther.12(8), 883–892 (2001).
   PubMed Web of Science ®Google Scholar

Websites

• WHO. Hepatitis B factsheet www.who.int/mediacentre/factsheets/fs204/en/
   Google Scholar
• CDC. Hepatitis B – CDC fact sheet 2006 www.cdc.gov/std/hepatitis/STDFact-Hepatitis-B.htm
   Google Scholar
• CDC. Key facts about influenza and the influenza vaccine www.cdc.gov/flu/keyfacts.htm
   Google Scholar
• CDC. Malaria facts www.cdc.gov/malaria/facts.htm
   Google Scholar
• UNAIDS/WHO. Global AIDS epidemic continues to grow www.who.int/hiv/mediacentre/news62/en/index.html
   Google Scholar
• CDC. Ebola hemerrhagic fever information packet www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Ebola_Fact_Booklet.pdf
   Google Scholar
• VRC. West Nile virus vaccine development www.vrc.nih.gov/scientificupdates_westnile.htm
   Google Scholar
• Vical. Vical Announces initiation of Phase I clinical trial with anthrax vaccine http://phx.corporate-ir.net/phoenix.zhtml?c=83618&p=irol-newsArticle&ID=594149 &highlight=anthrax
   Google Scholar
• CDC. Genital HPV Infection – CDC Fact Sheet 2004 www.cdc.gov/std/HPV/STDFact-HPV.htm
   Google Scholar
• Vical. Partnership programs www.vical.com/products/partnership_programs.htm
   Google Scholar
• HVTN. Current vaccine trials www.hvtn.org/science/trials.html
   Google Scholar
• HTVN. Questions and answers: HTVN 204 vaccine trial www.htvn.org/204/htvn204en.pdf
   Google Scholar